CorDx
Global rapid testing & point-of-care diagnostics
Chief Financial Officer
About the job
- A Master's degree in Finance or Accounting is required.
- At least 10 years of experience in finance, including at least 5 years in a senior leadership role, is required.
- Certified Public Accountant certification is required.
- Successful initial public offering experience is required.
- Strong financial analysis, strategic planning, and risk management skills are required.
- Mandarin-speaking ability is required.
- Each prior position must have lasted at least 3 years.
- Experience in life science, in-vitro diagnostics, medical diagnostics, or medical device manufacturing is required.
- Develop and implement financial strategies aligned with the company’s long-term goals, with a focus on initial public offering preparation.
- Oversee budgeting, forecasting, and scenario analysis.
- Ensure timely and accurate financial reporting in accordance with Securities and Exchange Commission regulations, United States Generally Accepted Accounting Principles, and Sarbanes-Oxley Act compliance.
- Oversee quarterly and annual financial statements and investor reports.
- Lead financial audits and regulatory filings.
- Optimize cost structures and allocate resources efficiently.
- Implement cost-saving initiatives without compromising product quality or research and development progress.
- Develop and execute financing strategies, including debt and equity financing, to support business growth.
- Manage relationships with investors, financial institutions, and external auditors.
- Identify and mitigate financial risks, including credit, liquidity, and operational risks.
- Develop internal control frameworks to ensure financial integrity.
- Build and lead a high-performing finance team.
- Ensure continuous development and training for finance team members.
- Partner with research and development, Operations, and Sales teams to ensure financial alignment with business objectives.
- Provide financial insights and strategic guidance to executive leadership.
About the company
CorDx is a multinational biotech organization that provides rapid testing and point-of-care diagnostic devices. Its products are designed to quickly detect infectious diseases (like COVID-19), pregnancy, drugs of abuse, biomarkers, and other health indicators directly at the patient’s side. The devices work by offering fast diagnostic tests and wearable or handheld systems that deliver results on-site, often supported by data science and artificial intelligence to improve accuracy and capture health data. CorDx differentiates itself from competitors through its global reach (2,100+ employees in over 100 countries), scale, and its emphasis on integrating AI and data-driven insights to enhance diagnostic solutions. The company aims to help answer critical health questions by delivering practical, accessible diagnostics and moving toward personalized healthcare.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Atlanta, Georgia
Founded
2006
Get referred to CorDx
See people who can refer or advise you
Simplify's Take
What believers are saying
- CorDx secured an FDA EUA for Tyfast Flu A/B and COVID-19 in 2024.
- The 2025 Singapore POCT Centre broadens access to infectious, fertility, and chronic-disease programs.
- CorDx opened a new Singapore facility in 2026, strengthening global manufacturing reach.
What critics are saying
- FDA authorization still governs key products like Tyfast and COVID-19 Ag under emergency use.
- Singapore expansion raises fixed costs while diagnostics demand remains volatile after pandemic-era normalization.
- Any U.S. FDA or EU IVDR setback would strand CorDx's multiplex-test commercialization roadmap.
What makes CorDx unique
- CorDx spans R&D, manufacturing, and supply chain across the U.S., China, and Singapore.
- The 2025 DxD Hub POCT Centre deepens CorDx's Singapore diagnostics collaboration.
- MasterControl adoption signals a compliance-first operating model across global quality and manufacturing systems.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Training Programs
Paid Vacation
401(k) Retirement Plan
Meal Benefits
Company News
CorDx selects MasterControl to streamline life science quality and manufacturing processes globally.
SAN DIEGO--(BUSINESS WIRE)--CorDx, a biotechnology company that is transforming the global diagnostics industry with innovative RD solutions, a vertically integrated supply chain, and manufacturing footprints in the United States and around the world, today announced a transformative $21M gift to the University of California San Diego’s Jacobs School of Engineering from CorDx founder Aiiso Yufeng Li (Jeff), with support from members of the CorDx family – Li’s wife, Aiiso DongDong Li (Doreen), Mac Chen, Haixia Yang, Monica Hu, and others at CorDx. The gift is designated to support chemical and nano engineering research and education at UC San Diego. In recognition of the gift, which marks a significant milestone in the family’s entrepreneurial and philanthropic journey, UC San Diego is renaming the department that houses the university’s chemical and nano engineers -- the Aiiso Yufeng Li Family Department of Chemical and Nano Engineering. This landmark contribution underscores the family’s unwavering dedication to advancing education and innovation and enhancing people’s lives worldwide. The donation is also a testament to the rise of chemical engineering and nano engineering, which is on a trajectory to soon achieve the same recognition and renown as bioengineering, revolutionizing industries and driving innovation to new heights